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Background: Kidney transplantation has improved survival and quality of life for patients with end-stage renal disease.
Despite excellent short-term results due to better and more potent immunosuppressive drugs, long-term survival of
transplanted kidneys has not improved accordingly in the last decades. Consequently there is a strong interest in
immunosuppressive regimens that maintain efficacy for the prevention of rejection, whilst preserving renal structure
and function. In this respect the infusion of mesenchymal stromal cells (MSCs) may be an interesting immune suppressive
strategy. MSCs have immune suppressive properties and actively contribute to tissue repair. In experimental animal studies
the combination of mammalian target of rapamycin (mTOR) inhibitor and MSCs was shown to attenuate allo immune
responses and to promote allograft tolerance. The current study will test the hypothesis that MSC treatment, in
combination with the mTOR inhibitor everolimus, facilitates tacrolimus withdrawal, reduces fibrosis and decreases the
incidence of opportunistic infections compared to standard tacrolimus dose.
Methods/design: 70 renal allograft recipients, 18–75 years old, will be included in this Phase II, open label, randomized,
non-blinded, prospective, single centre clinical study. Patients in the MSC treated group will receive two doses of
autologous bone marrow derived MSCs IV (target 1,5x106, Range 1-2x106 million MSCs per/kg body weight), 7 days apart,
6 and 7 weeks transplantation in combination with everolimus and prednisolone. At the time of the second MSC
infusion tacrolimus will be reduced to 50% and completely withdrawn 1 week later. Patients in the control group will
receive everolimus, prednisolone and standard dose tacrolimus. The primary end point is to compare fibrosis by
quantitative Sirius Red scoring of MSC treated and untreated groups at 6 months compared to 4 weeks post-transplant.
Secondary end points include: composite end point efficacy failure (Biopsy Proven Acute Rejection, graft loss or death);
renal function and proteinuria; opportunistic infections; immune monitoring and “subclinical” cardiovascular disease
groups by assessing echocardiography in the different treatment groups.
Discussion: This study will provide information whether MSCs in combination with everolimus can be used for
tacrolimus withdrawal, and whether this strategy leads to preservation of renal structure and function in renal recipients.
Trial registration: NCT02057965.
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Kidney transplantation has improved life expectancy and
quality of life for patients with end-stage renal failure.
However, despite the impressive improvements in short-
term outcome parameters due to better and more potent
immunosuppressive drugs, the long-term survival of
renal allografts has changed little during the past de-
cades [1]. A number of factors, such as quality of the
graft, ischemia/reperfusion (I/R) injury, ongoing cellular
and humoral alloreactivity and/ or calcineurin inhibitors
(CNI) may adversely affect renal structure causing early
tubular atrophy and interstitial fibrosis (IF/TA). CNI
have been the cornerstone of immunosuppressive ther-
apy for many years, due to their efficacy in preventing
acute rejection. However, CNI have nephrotoxic side ef-
fects that can directly contribute to renal dysfunction
and compromise long-term outcomes. Consequently,
there is a clear need for immunosuppressive regimens
that maintain efficacy for the prevention of rejection,
whilst preserving renal function and structure. The im-
mune regulatory properties of mesenchymal stromal
cells (MSCs) in both cellular and antibody mediated in-
flammatory models have highlighted their potential to
regulate the immune response after solid organ transplant-
ation [2]. In addition, MSCs have been shown to amelior-
ate I/R injury and to exert reparative properties. The
administration of MSCs might be an optimal strategy to
facilitate CNI withdrawal and to minimize immune sup-
pression. In addition, both MSCs and everolimus might
improve cardiovascular status and this strategy might be
an opportunity to reduce the toll of cardiovascular disease
following kidney transplantation.
Mesenchymal stromal cells
MSCs are multi potent cells that can be isolated from the
bone marrow (BM) and many other sources. There is cur-
rently not a single marker that can distinguish MSCs from
other cell types. Functional characterization of MSCs re-
lies primarily on their ability to adhere to plastic and their
differentiation potential. The International Society of Cel-
lular Therapy stated that MSCs should bear at least the
stromal markers CD73, CD90 and CD105, in addition to
the absence of the hematopoietic markers CD14, CD34
and CD45 [3,4]. Important for their possible clinical appli-
cation is that MSCs are easily isolated as they adhere to
plastic and are capable of substantial proliferation and ex-
pansion in culture [5]. Another advantage is that MSCs
can be cryopreserved with no loss of phenotype or differ-
entiation potential [6].
Several studies suggest that MSCs may play a role in
modulation of immune responses as extensively reviewed
[7,8]. Indeed, MSCs can down regulate many immune ef-
fector functions and have also been found to induce regu-
latory cells [9,10]. These immune modulatory propertiesmake MSCs especially attractive for potential use in treat-
ing disease driven by an immune response, including
transplant rejection [7,8,11,12]. In addition, MSCs have
been shown to improve tissue damage in response to in-
jury. In animal models, MSC administration decreased
fibrosis in the heart [13], and other organs such as the
lung, liver and kidney [14-18]. Several cytokines have been
shown to mediate the anti-fibrotic properties, including
BMP-7 [18] and HGF [19]. In addition, various models
have shown reparative properties in cardiovascular disease
[20]. This is of importance for transplant recipients since
cardiovascular disease causes significant morbidity and
mortality in these patients. Different studies have sug-
gested that the capacity of MSCs to produce paracrine fac-
tors plays a prominent role in affecting tissue repair and
immune modulation [11,21].
Mesenchymal stromal cells and solid organ
transplantation
Beneficial immune modulatory effects of MSCs have
been shown in experimental models of allo immune dis-
orders. In the case of solid organ transplantation, the
use of MSCs for several indications have been tested, in-
cluding treatment of I/R injury, prevention of IF/TA,
minimization of immune suppression and reversal or
stabilization of chronic transplant inflammation and fi-
brosis as recently reviewed [22]. Ongoing immune injury
to the graft may be caused by cellular and/or humoral
mechanisms accompanied by de novo donor specific
antibody (DSA) formation [23-25]. The importance of
these de novo DSA as a major cause of allograft failure
in the long term has recently been confirmed in numer-
ous studies [23,25]. Importantly, it was shown that DSAs
with the ability to activate complement, as determined by
binding of C1q, are associated with greater risk of acute
rejection and allograft loss [24]. By their immunosuppres-
sive properties, MSCs may possibly serve an important
role to control lymphocyte and antibody induced damage
to the kidney.
In a rat heart transplantation model donor MSCs sup-
pressed allogeneic T-cell responses in vitro and in vivo
and intravenous administration of MSCs prolonged the
survival of transplanted hearts, possibly by induction of
allograft tolerance through changing the Th1/Th2 bal-
ance [26]. Interestingly, a recent study showed that heart
grafts, which were tolerized through third-party multi-
potent adult progenitor cells, could be retransplanted to
secondary hosts without immunosuppression [27]. In a
study by Casiraghi et al., pre transplant infusion of
MSCs prolonged the survival of semi-allogeneic (B6C3
in B6) murine heart transplants through the generation
of regulatory T cells. A single recipient-derived MSC in-
fusion given peri transplant was marginally effective, and
a single MSC dose given one day after transplantation
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timing. The same group investigated the optimal timing
for MSC infusion to promote immune tolerance in a
murine kidney transplant model [28]. Pre-transplant
MSC infusion induced a significant prolongation of kid-
ney graft survival by inducing T regs [28], however post-
transplant infusion caused premature graft dysfunction
and failed to prolong graft survival. These results suggest
that the inflammatory milieu is of importance for the
mechanistic function of MSCs.
Two experimental studies are of particular interest
for our clinical protocol. After kidney transplantation,
Franquesa et al. observed a therapeutic effect of MSCs
attenuating the progression of IF/TA when this process
was already in progress [17]. Besides a reduction in IF/
TA, MSC-treated animals demonstrated fewer macro-
phages infiltrating the parenchyma, lowered expression of
inflammatory cytokines in combination with increased ex-
pression of anti-inflammatory factors [17]. In another ex-
perimental model, the combination of mTOR inhibitor
and MSCs was shown to attenuate alloimmune responses
and to promote allograft tolerance in heart transplants
[29]. Indeed, combination therapy of MSCs and low-dose
mTOR inhibitor rapamycin achieved long-term heart graft
survival (>100 days) with normal histology. The treated re-
cipients did accept donor skin grafts but rejected third-party
skin grafts, indicating the establishment of donor specific
tolerance. Tolerant recipients exhibited neither intragraft
nor circulating DSA, but demonstrated significantly higher
frequencies of both tolerogenic dendritic cells (Tol-DCs)
and CD4+CD25+Foxp3+T cells in the spleens [29].
A limited number of clinical studies have investigated
the role of MSCs in the transplant setting. Two studies
have focused on the role of MSCs in the early induction
phase. In a pilot study of safety and clinical feasibility, au-
tologous MSCs were tested in renal transplant recipients.
MSC infusion was shown to be feasible, allowing an in-
crease of T-reg in the peripheral blood and control of
memory CD8+T cell function [30]. In these patients, tim-
ing of the infusion seemed of major importance. Adminis-
tration of MSC in the early phase after transplantation
negatively affected kidney graft function, which was not
the case when MSCs were administered before transplant-
ation [31]. In a trial among 159 patients undergoing renal
transplantation, the use of autologous MSCs compared
with anti-IL-2 receptor antibody induction therapy re-
sulted in lower incidence of acute rejection, decreased risk
of opportunistic infection and better estimated renal func-
tion at 1 year [32]. Moreover, in a clinical pilot study allo-
geneic MSCs were administered in 6 renal transplant
recipients. Allogeneic donor derived MSCs combined with
low dose tacrolimus was safe and prevented acute rejec-
tion after renal transplantation [33], however immune
monitoring was not performed in this study.In our phase 1 clinical study safety and feasibility of
autologous MSC therapy was tested in HLA-DR mis-
matched patients with subclinical rejection (SCR) in
their renal biopsy at 4 or 24 weeks after renal transplant-
ation [34,35]. In total 6 patients received MSC infusion
which was feasible and well tolerated without adverse
events related to the treatment itself. In addition, initial
results suggested immune suppression after MSC ther-
apy. All patients that received MSCs demonstrated a
profound reduction in proliferation of patient peripheral
blood mononuclear cells (PBMCs) 12 weeks after MSC
infusion upon stimulation with donor specific PBMCs,
while the response to third party PBMCs was more
variable. Three patients developed opportunistic viral in-
fections, which might have been related to the MSC
treatment. In 2 patients with allograft rejection the infil-
trate had disappeared after the MSC infusion. In
addition, in patients diagnosed with IF/TA, the areas of
IF/TA disappeared after treatment with MSCs, indicat-
ing that MSCs might play a role as antifibrotic and rep-
arative treatment, which is one of the objectives in the
current study. Effects of MSC therapy in cardiovascular
disease have not been studied in previous clinical trials
in renal transplant recipients.
Methods and design
Objectives and endpoints
The primary end point of the current study is the level of
fibrosis, as determined by quantitative Sirius Red (SR) scoring
of biopsies of MSC treated and untreated groups at 6 months
compared to 4 weeks post transplantation. Other endpoints
include: composite endpoint efficacy failure (Biopsy Proven
Acute Rejection (BPAR), graft loss) at 6 months; renal func-
tion measured by eGFR (MDRD formula and iohexol clear-
ance) and proteinuria at 6 months; cytomegalovirus (CMV),
BK infection (viremia, disease and -syndrome) and other op-
portunistic infections; adverse events; the presence of DSA
and other phenotypical and functional aspects of the donor
specific immune response; to compare the progression of
“subclinical” cardiovascular disease in the different treatment
groups by assessing echocardiography.
Study design
The current trial is a 6-month, randomized, open-label,
non-blinded, prospective, single-center study of efficacy
and safety comparing concentration-controlled everoli-
mus and MSCs to everolimus with standard tacrolimus.
The protocol has been authorized by the Dutch Govern-
ment (CCMO) and by the Committee Medical Ethics of
the LUMC (Leiden University Medical Center).
In total, 70 de novo renal recipients, 18–75 years of age
will be recruited from the transplant clinics of the LUMC
and enrolled into the study if they meet the eligibility
criteria.
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For entry in the study, the following criteria must be met:
1. Female or male, aged between 18 and 75 years.
2. Subject is willing to participate in the study, must be
able to give informed consent and the consent must
be obtained prior to any study procedure.
3. Recipients of a first kidney graft from a deceased,
living-unrelated or non-HLA identical living related
donor > 50 years of age.
4. Panel Reactive Antibodies (PRA) ≤ 10%.
5. Patients must be able to adhere to the study visit
schedule and protocol requirements.
6. If female and of child-bearing age, subject must be
non-pregnant, non-breastfeeding, and use adequate
contraception.Exclusion criteria
1. Double organ transplant recipient.
2. Biopsy proven acute rejection (according to the
Banff criteria) in the first 6 weeks after
transplantation.
3. Patients with evidence of active infection or
abscesses (with the exception of an uncomplicated
urinary tract infection) before MSC infusion.
4. Patients suffering from hepatic failure.
5. Patients suffering from an active autoimmune
disease.
6. Patients who have had a previous BM transplant.
7. A psychiatric, addictive or any disorder that
compromises ability to give truly informed consent
for participation in this study.
8. Use of any investigational drug after transplantation.
9. Documented HIV infection, active hepatitis B,
hepatitis C or TB according to current
transplantation inclusion criteria.
10. Subjects who currently an active opportunistic
infection at the time of MSC infusion (e.g., herpes
zoster [shingles], CMV, Pneumocystis carinii
(PCP), aspergillosis, histoplasmosis, or
mycobacteria other than TB, BK) after
transplantation.
11. Malignancy (including lymphoproliferative disease)
within the past 2-5 years (except for squamous or
basal cell carcinoma of the skin that has been treated
with no evidence of recurrence) according to current
transplantation inclusion criteria.
12. Known recent substance abuse (drug or alcohol).
13. Contraindications to undergo a BM biopsy.
14. Patients who are recipients of ABO incompatible
transplants.
15. Cold ischemia time >30 hrs.16. Patients with severe total hypercholesterolemia
(>7.5 mmol/L) or total hypertriglyceridemia (>5.6
mmol/L) (patients on lipid lowering treatment with
controlled hyperlipidemia are acceptable).
Thirty five of the patients will be included in the everoli-
mus/MSC group and 35 patients in the everolimus/stand-
ard dose tacrolimus group (Figure 1, study scheme). All
patients will receive steroids and induction treatment with
alemtuzumab at day 0 and day 1 (15 mg subcutaneously).
BM will be harvested just prior to the renal transplantation
only from patients randomised to the MSC treatment
group. MSCs will be cultured in the GMP laboratory, as
previously described [34]. Patients will receive 2 doses of a
target of 1,5×106 MSCs per/kg body weight (range 1-
2×106) at weeks 6 and 7 after transplantation. The dose of
tacrolimus will be reduced to 50% at the time of the second
MSC infusion and completely withdrawn 1 week later. At
that time point the patient will receive 15 mg prednisolon.
The expected period of patient accrual is approximately
24 months. All study procedures will take place at the
LUMC.
Study procedures
Subjects will be seen in accordance with the assessment
schedule listed below (Table 1).
Isolation of bone marrow and infusion of MSCs
BM will be aspirated from the posterior iliac crest
of all patients under general anesthesia during the
renal transplantation. A total volume of 100 a 120 ml
will be harvested. The processing of the cells will take
place at the GMP Stem Cell Laboratory Facility of the
LUMC.
In consented patients, a clinical re-evaluation will be
undertaken before the planned infusion of MSCs. A
target of 1,5×106 MSCs per/kg body weight (range
1-2×106) will be infused within 30 minutes as indicated.
Actual doses of MSCs administered will be documented for
each patient. Close monitoring of vital signs (temperature,
pulse, respiratory rate, blood pressure, and oxygen satur-
ation) will be measured and documented before MSC
infusion, every 15 minutes in the first hour and every 30
minutes in the second hour after infusion.
Data collection
Patients enrolled in this study will undergo standard pre-
transplant work-up, which consists of baseline clinical
data (demographics, medical history, current medication,
previous blood transfusions, percentage of panel reactive
antibodies, infection status (see below), physical examin-
ation, laboratory examinations, urinalysis, electrocardio-
gram, chest X-ray, infection screening). For women, the
menopausal status will be recorded. The pregnancy test
Figure 1 Study scheme. In total 70 patients will be included in the study, 18–75 years old. Patients will be randomised prior to transplantation.
Thirty five of these patients will be included in the Certican®/MSC group and 35 patients in the Certican®/standard dose tacrolimus group. All
patients will receive steroids (100 mg at day 1 to 3, 50 mg at day 4, 20 mg at day 5 to 15, 15 mg at day 15 to 21, and 10 mg after day 22) and
induction treatment with alemtuzumab at day 0 and 1 (15 mg subcutaneously)*. Certican® dose will be 1.5 mg b.i.d. with trough levels between
3 and 8 ng/ml. Tacrolimus will be started orally 3 h before surgery (initial dose 2x5 mg ). In the first 6 weeks target trough levels are aimed at
10 ng/ml (range 8 to 12 ng/ml) for tacrolimus and thereafter 6–8 ng/ml. In the MSC treated group, BM will be harvested just prior to the renal
transplantation and MSCs will be cultured in the GMP laboratory. Patients will receive 2 doses of a target of 1,5x106 autologous BM MSCs per/kg
body weight IV (range 1-2x106) 7 days apart, 6 and 7 weeks after transplantation. The dose of tacrolimus will be reduced to 50% at the time of
the second MSC infusion and completely withdrawn 1 week later. Patients will receive at that time point 15 mg of prednisolone. In all patients a
renal biopsy will be performed at 4 weeks and at 6 months and scored according to the Banff criteria.









Week D0 W4 a 5 W6 W7 W8 W9 W10 W12 W14 W16 W20
BM harvesting X
MSC expansion, generating X
Informed consent X
Medical history X X X X X X X X X X X X
Concomitant medication X X X X X X X X X X X X
Transplantation information X X X X X X X X X X X X
Physical examination X X X X X X X X X X X X
Routine lab X X X X X X X X X X X X
Viral load CMV and BK X X X X X X X
Urinalysis X X X X X X X X X X X X
MSC infusion X X
Renal biopsy X X
Sera for storage X X X X
Iohexol clearance X
Blood for immune monitoring X X X X X
DSA X X# X
Safety assessment X X X X X X X X X X X X
Echo cardiography and pulse
wave velocity
X
Follow up study visits are planned at baseline, day of transplantation, during the renal biopsy (week 4 a 5), during the first and second MSC infusion at week
and 7, week 8, 9, 10, 12, 14, 16, 20, 24 after transplantation.
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standard transplantation criteria). Results must be avail-
able and negative prior to administration.
Intraoperative data (warm and cold ischemia time,
blood loss) and background information of the donor
(age, gender, race, height, weight, type of allograft (living
related or unrelated), infection status, serum creatinine)
and HLA (mis)match will also be documented. All im-
munosuppressive and other drugs used and dosages ad-
ministered will be recorded during the study.(Opportunistic) infections
HBsAg, Hepatitis C and HIV evaluated for screening will
be performed standard before transplantation. Earlier
tests, within 6 months prior to baseline are acceptable.
CMV (PCR-positive), EBV (PCR-positive), BK-viruria in
urine samples and BK-viremia in blood samples (RT-PCR)
will be measured at baseline, week 4, 6, 7, 8, 10, 14, 20 and
24. Other infections (including urinary tract infections,
pulmonary infections, herpes simplex) will be recorded as
well. Patients are treated routinely with valganciclovir
profylaxis per os for 6 months except for a CMV negative
donor recipient status. In addition, all patients receive
6 months of cotrimoxazole prophylaxis against pneumo-
cystis jirovecii pneumonia.Renal function
Glomerular filtration rate (GFR calculation) will be used
to measure the renal function. The following abbreviated
MDRD formula will be used for GFR estimation eGFR
[mL/min/1.73 m2] = 186.3x SCr-1.154 × Age-0.203 ×
(0.742 if female) × (1.21 if black). In addition we will
measure renal function with iohexol clearance at week 4
and 24. The iohexol clearance will be performed at the
day of the renal biopsies.Fibrosis scoring by renal biopsy
A standard renal protocol biopsy is performed prior to the
transplantation and at 6 months after transplantation. At
4 weeks after transplantation a study biopsy is taken to as-
sess the renal histology before MSC infusion. Biopsies are
scored according to the Banff criteria and processed for
immunohistochemistry (HE staining; staining for CD3,
CD4, CD68, FOXp3, C4d and CD20). In addition, the
amount of cortical collagen (SR-positive area) will be mea-
sured and finally expressed as the percentage of the total
analyzed cortical surface. Moreover, changes in mRNA ex-
pression of pro- and anti-fibrotic genes (including FGFb
and fibronectin) in renal biopsies taken before and after
MSC infusion through real-time quantitative PCR will be
performed.Cardiovascular follow-up
Left ventricular internal dimension and wall thickness
will be measured at end-diastole and at end-systole ac-
cording to recommendations of American Society of
Echocardiography. End diastolic left ventricular septal
and posterior wall thicknesses and internal dimensions
will be used to calculate left ventricular mass. Echocardi-
ography will be performed at week 4 and week 24.Immune modulating capacities before and after MSC
infusions
DSAs will be measured at baseline (before transplantation),
time of renal biopsy, 12 weeks and 6 months after trans-
plantation and every time a for-cause allograft biopsy is
performed. For immunological monitoring, we will collect
sera and PBMCs at different times post transplantation as
described. Phenotypical analyses of the different leucocyte
subpopulations will be performed on basis of the immune
panels developed and validated for the One Study [36].
In addition mixed lymphocyte reaction assays of recipi-
ent’s PBMCs will be performed sequentially with the use of
frozen cells obtained before transplantation to compare re-
sponses to the donor cells before and after transplantation
[37]. Supernatants of these MLR cultures will be collected
for analyses of cytokine profiles. Direct cross-matches of re-
cipient sera and donor lymphocytes will be done by com-
plement dependent cytotoxicity (CDC) and flow-cytometric
assays. PBMCs will be stimulated using CD3/CD28 and an-
alyzed for TH1 (i.e. interleukin-2 and interferon-γ), TH2
(IL-10 and IL-4) and inflammatory cytokines (i.e. tumor ne-
crosis factor-α, TGF-β, IL-1 and IL-6).Data safety monitoring committee
The DSMB will monitor the safety of subjects. The
DSMB consists of two independent physicians and one
biostatistician. The DSMB will meet at least after inclu-
sion of 20 and 50 subjects. They will judge on the rate of
rejections and serious adverse events (SAEs) in the
study. We regard a 30% rejection rate and over to be
unacceptable; this will lead to study termination. The
DSMB will review all serious adverse events unblinded
and determine, based on a careful consideration of
the events, whether the SAE is most likely related to
MSCs. This review will take all aspects into account,
including onset of the SAE relative to MSC infusions,
other potential causes for the SAE such as concomitant
medication and underlying conditions, and other previous
adverse events observed over the course of the study. Only
SAE that were assessed by the DSMB as most likely
related to MSC will be taken into account for the decision
to proceed with the study. The DSMB has the right to
terminate the study.
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In our study a sample size of 25 in each group (or 50 in
total) will have a 80% power to detect a difference in
mean percentages of fibrosis of at least 25% using a two
group t-test with a 0.05 two-sided significance level
(alpha). In this calculation we used the following as-
sumptions: we expect the control group (no MSC’s) to
have a mean percentage of fibrosis of 18% at 6 months
[38-43]. We assume that both groups show equal vari-
ability in measured fibrosis and that the common stand-
ard deviation is 5% [40]. A mean percentage of 14% in
MSC group (25% less fibrosis) is considered a clinically
relevant difference. We anticipate that 70% of included
patients will have valid measurements (withdrawal in-
cluded). We therefore plan to include 70 patients in
total, 35 in the MSC group and 35 in the control group.
Risk-benefit assessment
The high prevalence of nephrotoxicity suggests that CNI
are unsuitable as long-term immunosuppressive agents
for kidney transplantation and MSCs might offer an al-
ternative treatment modality with the aim to inhibit fi-
brosis and to prolong allograft survival. In previous
studies in transplant recipients, MSC therapy was shown
to be feasible and no major serious side effects have
been reported so far. One of the risks of CNI withdrawal
is an increased risk of acute allograft rejection. Therefore
renal function and trough levels of the immune suppres-
sive drugs will be monitored frequently. In addition, the
type of induction therapy (alemtuzumab) and the timing
of CNI withdrawal (>6 weeks) are chosen to minimize
risks for allograft rejection. We think that early clinical
results, which suggest beneficial effect from MSC ad-
ministration for patients after renal transplantation and
the expected limited possibility on adverse side effects
justify participation in this study.
Discussion
The great potential for MSC therapy to become a new
tool after renal transplantation as immune suppressive
and reparative treatment is strengthened by positive pre-
clinical results, the ease of isolation and expansion of
MSCs and encouraging preliminary trials. Since current
immunosuppressive drugs cannot be withheld from pa-
tients receiving MSC treatment after renal transplant-
ation, it is of importance that an optimal concurrent
immunosuppressive regimen is chosen with minimal
side effects. The objective of the current study is to im-
plement MSC treatment in combination with everolimus
to facilitate CNI withdrawal with the aim to preserve
renal function and structure.
Since the early 1980, the standard approach to immuno-
suppression in transplant recipients has involved the use
of CNI such as cyclosporine (CsA) and tacrolimus. Mostcentres nowadays use a regimen of basiliximab, mycophe-
nolate mofetil (MMF), and corticosteroids in combination
with low-dose tacrolimus, based on the Symphony trial
[44]. However, immune suppressive drug treatment is be-
coming more and more individualized. CNI nephrotox-
icity may account for the paradox that the reduction or
abolition of early episodes of acute rejection has not re-
sulted in commensurate improvements in the long-term
outcome [1,45]. The damage by CNI is not reversed by
mild-to-moderate reductions in the dose of these agents
[45]. However, the optimal treatment strategy to reduce or
eliminate CNI therapy at an early time point after trans-
plantation, without compromising efficacy, is unclear. In
this perspective MSCs might facilitate CNI withdrawal. In
our protocol, we have chosen for the combination of
MSCs with everolimus, prednisolone and alemtuzumab.
The combination of an mTOR inhibitor and MSCs might
be a potential promising strategy since there is experimen-
tal evidence that this combination is tolerogenic [2,9,29]
and capable of increasing regulatory immune cells [29]. Of
importance, complete avoidance and replacement of a
CNI by everolimus in de novo transplant recipients is not
justified, since this strategy previously resulted in un-
acceptable high acute rejection rates even with induction
therapy [46]. Both the Caesar and the Symphony study
showed that reduced CNI-dosing, as opposed to full dose
CNI early after transplantation, are equally efficacious in
preventing acute rejection but only marginally improved
renal function parameters [44,47]. The CONVERT and
the ASCERTAIN study were initiated to replace CNIs
by an mTOR inhibitor at a late time-point i.e., 3,2 and
5,6 years respectively, after transplantation [48,49]. This
strategy proved to be safe but again only minor improve-
ments in renal function parameters were found and if so,
predominantly in patients with still preserved renal func-
tion. Contrastingly, in the Zeus study, renal allograft recip-
ients were converted from CNI to everolimus at 4–5
months after transplantation to triple drug regimen with
mycophenolate and steroids and reported significantly bet-
ter renal function up to 3 years after CNI-elimination
[50,51]. In our study, CNI will be withdrawn at an earlier
time point, namely at 6 weeks after transplantation. To de-
crease the risk for acute rejections, MSCs will be infused
at the time of CNI withdrawal. In addition, alemtuzumab
will be used as induction treatment. This induction treat-
ment has been shown to be superior to traditional anti-
bodies in preventing acute rejection. A recent study
demonstrated that alemtuzumab-based induction therapy
followed by reduced CNI and mycophenolate exposure
and steroid avoidance reduced the risk of biopsy-proven
acute rejection compared with standard basiliximab in a
broad range of patients receiving a kidney transplant [52].
One of the important issues in the MSC-based clinical
trials is defining endpoints, as this is the measure of trial
Reinders et al. Journal of Translational Medicine 2014, 12:331 Page 8 of 11
http://www.translational-medicine.com/content/12/1/331failure or success. However, this is very challenging in
patients after solid organ transplantation, where an in-
creased risk for infections and malignancies already ex-
ists and where there is a lack of validated surrogate
markers of disease. The therapeutic aim of MSC-based
trials in renal transplant recipients is to induce immune
suppression and repair of damaged tissue but without
the risk of inducing tumours, infections, or unwanted
tissue development, and obviously without increasing
allograft rejection rates and diminishing allograft sur-
vival. Therefore both safety and efficacy measures have
to be addressed. Efficacy markers in our trial include la-
boratory studies to determine possible development of
donor-specific immunosuppression and histopathologic
evaluation of renal tissue to evaluate both inflammation
and fibrosis before and after the treatment. The primary
endpoint in our study is the comparison of fibrosis by
quantitative SR scoring of MSC treated and untreated
groups at 6 months compared to 4 weeks post-transplant.
Once established, interstitial fibrosis and arteriolar hyalino-
sis lead to progressive glomerulosclerosis over the subse-
quent years. In earlier studies nephrotoxicity, implicated in
late ongoing injury, has been shown to be almost universal
at 10 years, even in grafts with excellent early histologic
findings. By 10 years, severe chronic allograft nephropathy
was present in 58.4% of patients, with sclerosis in 37.3% of
glomeruli. Tubulointerstitial and glomerular damage, once
established, was irreversible, resulting in declining renal
function and graft failure [38,53-56]. Functional studies
underestimate the extent of allograft disease as supported
by longitudinal studies of protocol renal biopsies showing
histologic features of IF/TA in well-functioning grafts
[38,39,56-58]. Therefore, early histologic detection of IF/
TA has been suggested to be helpful in predicting the risk
for subsequent loss of function and time to graft failure
and to estimate the efficacy of therapeutic measures. Semi-
quantitative grading systems such as Banff scores have a
wide inter-observer variation that makes comparison
across centers inaccurate. In contrast, computerized image
analysis of fractional interstitial fibrosis of SR-stained biop-
sies has been shown to be a valid and reproducible method
to measure the degree of fibrosis [40,41,43,59,60]. SR dye is
specific for collagen types I and III, which represent re-
spectively 80 and 20% of total collagen synthesized by fi-
broblasts and thereby important components of renal
matrix. Quantification of renal interstitial volume assessed
by SR nonpolarized technology has been validated and cor-
related significantly with GFR as measured by iothalamate
clearance in cases of established chronic allograft nephrop-
athy [59]. In addition, in 2011 morphometric and visual
evaluation of fibrosis by various techniques was compared
and Collagen III, SR unpolarized had strongest correla-
tions, greatest dynamic range and the best correlation with
estimated GFR [61].As secondary endpoints safety measures will be in-
cluded. An important safety issue includes direct toxicity
related to the infusions. Although, to date, no toxicity
has been observed during intravenous MSC infusion
[11], a possible side-effect of MSC transfusion could be
a transfusion reaction (e.g. allergic reaction, fever and
hypotension). Another possible side effect could be an
increased risk of infection; therefore all donors are thor-
oughly screened before BM aspiration. In addition, one
cannot rule out that a renal transplant recipient receiv-
ing MSCs might have a decrease of renal function. In
addition, the change in immune suppressive regimen
might increase the incidence of acute rejection.
Other potential risks which should be considered when
using MSCs for clinical applications include risk for malig-
nancies and opportunistic infections. So far, in clinical tri-
als using MSCs no malignancies have been reported.
However most trials have a short follow up and we are still
awaiting reports on long-term effects [20,62,63]. More-
over, in many trials patients with a poor prognosis are in-
cluded where MSC-related side effects might be obscured.
In addition, due to the concomitant use of immunosup-
pressive medications, patients who received a renal trans-
plant are already at enhanced risk of malignancies.
The risk of over immunosuppression, which may lead
to opportunistic infections, has been studied in a few re-
ports and will be closely monitored in our trial as well.
In a study by Tan et al. on patients undergoing renal
transplantation [32], the use of autologous MSCs instead
of anti-IL-2 receptor antibody induction therapy resulted
in decreased opportunistic infections (including CMV
infections). However, CMV donor recipient status was
negative in 151 of 154 patients, which might have caused
the low incidence of CMV infections in their population.
In our previous trial, 3 out of 6 renal recipients devel-
oped opportunistic infections [34] and also MSC co-
infusion after haematopoietic stem cell transplantation
(HSCT) caused a higher 1-year incidence of (particularly
fungal) infections [64]. It is clear that frequent and ac-
curate monitoring of infectious complications and also
monitoring of the level of immune suppression remains
essential.
A number of factors may adversely affect renal struc-
ture and function, including ongoing alloimmune injury
by cellular and immune reactions. It is therefore of
major importance that the immune status is accurately
measured in our trial population. Our current protocol
will measure DSA at several time points and will encom-
pass a robust immune monitoring strategy, developed by
the ONE study consortium which includes procedures
for whole blood leukocyte subset profiling by flow cy-
tometry [36]. Our hypothesis is that MSCs induce im-
mune suppression by decreasing the amount of effector
cells and increasing the number of regulatory cells. In
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MSCs demonstrated a profound reduction in proliferation
of PBMC 12 weeks after MSC infusion upon stimulation
with donor PBMCs, but there were no consistent changes
in immune profiles. In the pilot study by Perico et al. MSC
treatment allowed increased numbers of T regs in the per-
ipheral blood and control of memory CD8+T cell function
[30]. In both studies the amount of included patients was
small and it is therefore difficult to draw firm conclusions.
In addition, both studies were set up as safety and feasibil-
ity studies. In the current trial we anticipate that we can
make meaningful comparisons of leukocyte subset profil-
ing in MSC treated and untreated groups.
Cardiovascular disease exerts a high burden in terms of
morbidity and mortality in renal recipients. The annual risk
of a cardiovascular event is up to 50-fold higher for a renal
recipient compared to the general population [65-67] and
over a third of all deaths following kidney transplantation
are caused by cardiovascular disease [68,69]. Several stud-
ies nowadays focus on the proposed cardio protective
effects of everolimus in transplant recipients. In heart
transplantation everolimus was significantly more effica-
cious than mycophenolate mofetil in preventing cardiac
allograft vasculopathy (CAV) as measured by intravascular
ultrasound (IVUS) among heart-transplant recipients after
1 year [70]. Interestingly, this process might be regulated
by T regs, which are expanded after treatment of an
mTOR inhibitor [71]. However, mTor inhibitors are also
capable to increase the frequency of antigen-specific CD8+T
cells that differentiated into the memory lineage, thus ad-
equate immune monitoring is of major importance [72]. As
MSCs have also been proposed to exert reparative proper-
ties in cardiovascular disease, the combination of MSCs
and everolimus might be an opportunity to reduce the toll
of cardiovascular disease following kidney transplantation.
Taken together, we hypothesize that infusion of MSCs
enables CNI withdrawal and provides a novel treatment
option for renal recipients with a profound effect on the
fibrosis reaction and less side effects than existing im-
munosuppressive therapies. A positive outcome from
MSCs in terms of safety and preservation of renal func-
tion and structure would implicate a major advancement
for renal transplant recipients.
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